These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26601857)

  • 1. Heterogeneity in Melanoma.
    Shannan B; Perego M; Somasundaram R; Herlyn M
    Cancer Treat Res; 2016; 167():1-15. PubMed ID: 26601857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of Melanoma with Stem Cell Properties.
    Seftor EA; Margaryan NV; Seftor REB; Hendrix MJC
    Adv Exp Med Biol; 2019; 1139():105-114. PubMed ID: 31134497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology of melanoma.
    Elder DE
    Surg Oncol Clin N Am; 2015 Apr; 24(2):229-37. PubMed ID: 25769708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma stem cells.
    Roesch A
    J Dtsch Dermatol Ges; 2015 Feb; 13(2):118-24. PubMed ID: 25631128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the staging of melanoma.
    Baruch AC; Shi J; Feng Y; Nelson MA
    Cancer Invest; 2005; 23(6):561-7. PubMed ID: 16203664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in Melanoma: Lessons from Translational Medicine.
    Buchbinder EI; Flaherty KT
    Trends Cancer; 2016 Jun; 2(6):305-312. PubMed ID: 28741528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of diagnostic, prognostic, and predictive biomarkers in melanoma.
    Ankeny JS; Labadie B; Luke J; Hsueh E; Messina J; Zager JS
    Clin Exp Metastasis; 2018 Aug; 35(5-6):487-493. PubMed ID: 29722000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward a molecular classification of melanoma.
    Fecher LA; Cummings SD; Keefe MJ; Alani RM
    J Clin Oncol; 2007 Apr; 25(12):1606-20. PubMed ID: 17443002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The classification of cutaneous melanoma.
    Duncan LM
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):501-13, ix. PubMed ID: 19464599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and biological heterogeneity of melanomas].
    Delyon J; Mourah S; Lebbé C
    Rev Prat; 2014 Jan; 64(1):72-3. PubMed ID: 24649551
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment.
    Marcell Szasz A; Malm J; Rezeli M; Sugihara Y; Betancourt LH; Rivas D; Gyorffy B; Marko-Varga G
    Cell Biol Toxicol; 2019 Feb; 35(1):1-14. PubMed ID: 30357519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers.
    Abbas O; Miller DD; Bhawan J
    Am J Dermatopathol; 2014 May; 36(5):363-79. PubMed ID: 24803061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target.
    Spanjaard RA; Whren KM; Graves C; Bhawan J
    Int J Cancer; 2007 Mar; 120(6):1304-10. PubMed ID: 17187358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification and staging of melanoma.
    Gershenwald JE; Buzaid AC; Ross MI
    Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.
    Eggermont AM; Keilholz U; Testori A; Cook M; Lienard D; Ruiter DJ
    Ann Surg Oncol; 2001 Oct; 8(9 Suppl):38S-40S. PubMed ID: 11599896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on primary mucosal melanoma.
    Tacastacas JD; Bray J; Cohen YK; Arbesman J; Kim J; Koon HB; Honda K; Cooper KD; Gerstenblith MR
    J Am Acad Dermatol; 2014 Aug; 71(2):366-75. PubMed ID: 24815565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment implications of the emerging molecular classification system for melanoma.
    Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
    Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β.
    Barak V; Leibovici V; Peretz T; Kalichman I; Lotem M; Merims S
    Anticancer Res; 2015 Dec; 35(12):6755-60. PubMed ID: 26637892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromatin barcodes as biomarkers for melanoma.
    Bastonini E; Jeznach M; Field M; Juszczyk K; Corfield E; Dezfouli M; Ahmat N; Smith A; Womersley H; Jordan P; Ramadass A; Akoulitchev A; Goding CR
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):788-800. PubMed ID: 24807349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.
    Sim GC; Chacon J; Haymaker C; Ritthipichai K; Singh M; Hwu P; Radvanyi L
    BioDrugs; 2014 Oct; 28(5):421-37. PubMed ID: 24890028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.